Here is the design of a clinical trial:

Official Title: Effects of Standard Protocol Therapy With or Without Colchicine in Covid-19 Infection: A Randomized Double Blind Clinical Trial

Included conditions:
- COVID-19

Study Armgroups:
- {'label': 'Intervention', 'type': 'ACTIVE_COMPARATOR', 'description': '40 RT-PCR positive COVID-19 patients without hypoxemia administered Colchicine plus standard treatment', 'interventionNames': ['Drug: Colchicine Tablets']}
- {'label': 'Standard treatment', 'type': 'NO_INTERVENTION', 'description': '40 RT-PCR positive COVID-19 patients without hypoxemia receiving vitamin C 3grams daily , 400 mg Tiamine, Selenium , Omega-3 500 mg daily, Vit A , Vit D, Azithromycine, Ceftriaxone, Kaletra 400 BID 10 days'}

Interventions:
- {'type': 'DRUG', 'name': 'Colchicine Tablets', 'description': '1.5 mg loading then 0.5 mg BID P.O', 'armGroupLabels': ['Intervention'], 'otherNames': ['Colchicine']}

Primary Outcomes:
- {'measure': 'CRPxN/R ratio change', 'description': 'increasing inflammatory status', 'timeFrame': '2 weeks'}
- {'measure': 'Clinical deterioration by the WHO definition', 'description': 'including change in fever or O2 Saturation', 'timeFrame': '2 weeks'}
- {'measure': 'PCR Viral Load', 'description': 'change in RT-PCR', 'timeFrame': '2 weeks'}
- {'measure': 'CT severity involvement index', 'description': 'change in CT involvement', 'timeFrame': '2weeks'}

Please estimate the sample size based on the assumption: 
Based on the center's capacity to hospitalize confirmed COVID-19 patients
Numbers to be randomised (sample size)
          Regarding the pandemic crisis and our center capacity to hospitalize confirmed COVID-19 patients, a total of 80 patients was found to be logical to be randomized into two groups of 40- patients.